Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Business & Industry
- Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
- Lilly and MiNA Therapeutics announce saRNA research collaboration
- Vaccination with Sputnik V launched in India
- Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study
- Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate
Research & Development
- COVID-19 mRNA vaccines are immunogenic in pregnant and lactating women
- Major differences in COVID patient care caused by insufficient data, misleading advice
- Researchers develop better way to determine safe drug doses for children
- WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
- Our immune systems blanket the SARS-CoV-2 spike protein with antibodies
- Using personalized medicine to avoid resistance to leukemia treatment
- Speeding new treatments
Conferences & Events
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic
- FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review
- FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
- Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
- AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets